What is Kura Oncology's market cap?

Kura Oncology (KURA) has a market capitalization of $1.1B and trades on NASDAQ.

What is Kura Oncology's revenue and profitability?

Kura Oncology generated $71.6M in trailing twelve-month revenue with a net loss of $294.6M, representing a net margin of -411.2%, with free cash flow of -$271.6M. These figures are based on the Q1 2026 filing.

Who are Kura Oncology's competitors?

Kura Oncology's key competitors include Syndax Pharmaceuticals, Janssen, AbbVie, and others. These companies compete in similar markets and product categories.

Who does Kura Oncology partner with?

Kura Oncology's notable partners include Kyowa Kirin, Mirati Therapeutics, Bristol Myers Squibb, and others.

Where is Kura Oncology headquartered?

Kura Oncology is headquartered in United States of America and employs approximately 142 people. It has been publicly traded since 2015.

Kura Oncology

KURA

Kura Oncology is a fully-integrated, commercial-stage biopharmaceutical company focused on developing precision medicines for cancer.

Market cap

$1.07B+94.8%

Revenue$71.6M+31.4%

Net income-$294.6M-62.0%

Free cash flow-$271.6M-303%

EPS (diluted)-$3.35-59.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$18.3MMiss by $7.7M EPS-$0.83Beat by $0.05

Read the full report

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$20.2M

EPS estimate-$0.89

Financials

Q1 2026

Income statement

See full

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

See full

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

See full

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation & ratios

Valuation

See full

Market cap$1.07B+94.8%

Enterprise value$1.06B+146%

P/S15×+6.2×

Profitability

See full

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

Returns & leverage

See full

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Segments

By product

See full

License And Collaboration Revenue$12.5M-11.4%

Development Services For Monotherapy$7.2M—

Development Services In Combination With Other Therapies$5.3M—

Competitors

By market cap

Johnson & Johnson$623.71B+66.9%

AbbVie$441.54B+33.2%

Amgen$196.25B+24.6%

Exelixis$14.4B+19.2%

Syndax Pharmaceuticals$2.2B+193%

Nuvation Bio$2.1B+201%

Corvus Pharmaceuticals$1.4B+353%

Kura Oncology$1.1B+118%

By revenue growth

Nuvation Bio+1,206%

Syndax Pharmaceuticals+397%

Kura Oncology+31.4%

AbbVie+9.5%

Amgen+9.1%

Johnson & Johnson+7.9%

Exelixis+3.3%

By net margin

Exelixis35.08%+7.1pp

Johnson & Johnson21.83%-2.6pp

Amgen20.96%+3.6pp

AbbVie5.79%-1.5pp

Nuvation Bio-102.06%+5,432pp

Syndax Pharmaceuticals-111.88%+646pp

Kura Oncology-411.19%-77.6pp

Profile

Kura Oncology is a fully-integrated, commercial-stage biopharmaceutical company focused on developing precision medicines for cancer. The company leverages translational research and molecular diagnostics to target specific cancer signaling pathways, aiming to improve patient outcomes through small molecule inhibitors. Its core value proposition lies in its ability to match targeted therapeutics to genetically defined patient populations in oncology and hematology.

Competitive position

Kura is a pioneer in the menin inhibitor class with the first FDA-approved oral once-daily therapy for NPM1-mutated AML.

GeographiesUnited States, Global

Customer segmentsPatients, Healthcare Providers, Payors, Biopharmaceutical Companies

Business modelProduct Sales, Licensing and Royalties, R&D Collaboration

SuppliersContract Manufacturing Organizations (CMOs), Diagnostic Technology Partners, Academic Research Institutions, Raw Material Suppliers

CustomersSpecialty Distributors, Specialty Pharmacies, Commercial Insurers, Government Payors (Medicare/Medicaid)

CountryUnited States of America

Listed2015

Employees142.0

CEOTroy Wilson

SectorHealthcare

IndustryBiotechnology

Websitekuraoncology.com

FilingsSEC EDGAR

Ask your AI about Kura Oncology.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kura Oncology's market cap?: Kura Oncology (KURA) has a market capitalization of $1.1B and trades on NASDAQ.
What is Kura Oncology's revenue and profitability?: Kura Oncology generated $71.6M in trailing twelve-month revenue with a net loss of $294.6M, representing a net margin of -411.2%, with free cash flow of -$271.6M. These figures are based on the Q1 2026 filing.
Who are Kura Oncology's competitors?: Kura Oncology's key competitors include Syndax Pharmaceuticals, Janssen, AbbVie, and others. These companies compete in similar markets and product categories.
Who does Kura Oncology partner with?: Kura Oncology's notable partners include Kyowa Kirin, Mirati Therapeutics, Bristol Myers Squibb, and others.
Where is Kura Oncology headquartered?: Kura Oncology is headquartered in United States of America and employs approximately 142 people. It has been publicly traded since 2015.